Payment overview · 2025
General Payments
$237.68
8 reported records · 6 companies
Healthcare provider profile · identity verified
Qi Wilson
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MIAMI, FL · NPI 1083180004
Verified facts
What the public records show
CMS Open Payments records show Qi Wilson received $237.68 in general payments during 2025 across 8 reported records.
ViiV Healthcare Company accounted for 50.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $120.32 | 50.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.65 | 15.4% | 2 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $25.38 | 10.7% | 1 | 2025 |
| Bavarian Nordic A/S | Unresolved — no canonical attribution shown | $19.07 | 8.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.82 | 7.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $17.44 | 7.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $237.68 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $100.23 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.65 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.65 | 2 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| Vivotif Normalized: vivotif |
Drug | Bavarian Nordic A/S | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 279 | 128 |
| Losartan Potassium | Losartan Potassium | 245 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 231 | 93 |
| Vascepa | Icosapent Ethyl | 165 | 49 |
| Metformin Hcl | Metformin Hcl | 134 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 120 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 116 | 51 |
| Simvastatin | Simvastatin | 100 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 90 | 50 |
| Donepezil Hcl | Donepezil Hcl | 87 | 31 |
| Eliquis | Apixaban | 81 | 54 |
| Alendronate Sodium | Alendronate Sodium | 77 | 22 |
| Famotidine | Famotidine | 76 | 39 |
| Ammonium Lactate | Ammonium Lactate | 74 | 28 |
| Montelukast Sodium | Montelukast Sodium | 72 | 33 |
| Glipizide Er | Glipizide | 70 | 23 |
| Omeprazole | Omeprazole | 65 | 38 |
| Folic Acid | Folic Acid | 58 | 24 |
| Fenofibrate | Fenofibrate,micronized | 55 | 17 |
| Finasteride | Finasteride | 51 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 51 | 32 |
| Farxiga | Dapagliflozin Propanediol | 48 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 14 |
| Allopurinol | Allopurinol | 46 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 26 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 43 | 27 |
| Levothyroxine Sodium | Levothyroxine Sodium | 42 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 42 | 40 |
| Jardiance | Empagliflozin | 41 | 21 |
| Lisinopril | Lisinopril | 40 | 20 |
| Furosemide | Furosemide | 39 | 27 |
| Meloxicam | Meloxicam | 35 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 33 | 17 |
| Januvia | Sitagliptin Phosphate | 32 | 11 |
| Gabapentin | Gabapentin | 29 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | 11 |
| Meclizine Hcl | Meclizine Hcl | 28 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 27 | 12 |
| Diclofenac Epolamine | Diclofenac Epolamine | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | 12 |
| Hydrocortisone | Hydrocortisone | 24 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 22 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 21 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | 19 |
| Mirtazapine | Mirtazapine | 20 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Baclofen | Baclofen | 19 | 14 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 18 |
| Icosapent Ethyl | Icosapent Ethyl | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 18 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 18 | 17 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | 15 |
| Azithromycin | Azithromycin | 16 | 16 |
| Carvedilol | Carvedilol | 16 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 15 |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | 11 |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $237.68 · 8 records | ViiV Healthcare Company | CABENUVA, CREON, DOVATO, MOUNJARO, Vivotif, ZEPBOUND, ZORYVE | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error